Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 20/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 19/20 | 1.00 |
| ▸ | AURKA | O14965 | 12/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 9/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 1/20 | 1.00 |
| ▸ | PDK1 | Q15118 | 1/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317022 | 1.00 | PDPK1 (1.00) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1317861 | 0.92 | PDPK1 (0.86) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1320418 | 0.91 | PDPK1 (1.00) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1319624 | 0.91 | PDPK1 (0.98) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1318073 | 0.90 | PDPK1 (0.82) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1318075 | 0.90 | PDPK1 (0.82) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1318076 | 0.90 | PDPK1 (0.82) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1316758 | 0.89 | PDPK1 (0.81) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1316760 | 0.89 | PDPK1 (0.81) | PDPK1AURKBAURKAROCK1PIK3CG | |
| SCHEMBL1316761 | 0.89 | PDPK1 (0.81) | PDPK1AURKBAURKAROCK1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605376-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-08-27 | — | — | EP | claimed |
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| WO-2025082502-A1 | PAN T CELLS AND METHODS OF MANUFACTURING OF THE SAME | NANJING LEGEND BIOTECH CO., LTD. (CN) | 2025-04-24 | — | — | WO | claimed |
| WO-2025080080-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, CONTAINING PDK INHIBITOR AS ACTIVE INGREDIENT | 한양대학교 산학협력단 | 2025-04-17 | — | — | WO | claimed |
| US-20240382484-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | THOMAS JEFFERSON UNIVERSITY | 2024-11-21 | — | — | US | claimed |
| US-12036241-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | claimed |
| WO-2024083802-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | VALDOSPAN GMBH (AT) | 2024-04-25 | — | — | WO | claimed |
| CN-111912826-B | Method for evaluating efficacy of antitumor drug at cellular level | 上海氘峰医疗科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| EP-4322949-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | RDP Pharma AG (CH) | 2024-02-21 | — | — | EP | claimed |
| CN-114831991-B | Application of GSK2334470 in preparing antifungal medicament and synergist thereof | 陕西科技大学 | 2024-02-06 | — | — | CN | claimed |
| WO-2024011307-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | claimed |
| CN-117377474-A | Isoquinoline derivatives as antiviral and antitumor agents | RDP制药股份公司 | 2024-01-09 | — | — | CN | claimed |
| US-11696924-B2 | Combination therapy using PDK1 and PI3K inhibitors | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-07-11 | — | — | US | claimed |
| WO-2023044386-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2023-03-23 | — | — | WO | claimed |
| WO-2022219157-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | VALDOSPAN GMBH (AT) | 2022-10-20 | — | — | WO | claimed |
| WO-2022192372-A1 | METHODS AND COMPOSITIONS FOR TUSC2 COMBINATION THERAPY WITH PDK1 INHIBITION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-15 | — | — | WO | claimed |
| CN-114831991-A | Application of GSK2334470 in preparation of antifungal drugs and synergist thereof | 陕西科技大学 | 2022-08-02 | — | — | CN | claimed |
| US-20220152116-A1 | MULTI-STAGE PERSONALIZED LONGEVITY THERAPEUTICS | INSILICO MEDICINE IP LIMITED (HK) | 2022-05-19 | — | — | US | claimed |
| US-11260078-B2 | Method of treating senescence with multi-stage longevity therapeutics | INSILICO MEDICINE IP LIMITED (HK) | 2022-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152116-A1 | MULTI-STAGE PERSONALIZED LONGEVITY THERAPEUTICS | SENP6, SENP1, GLA | PDPK1 2761/4885AURKB 1798/4885AURKA 2989/4885 |
| US-11260078-B2 | Method of treating senescence with multi-stage longevity therapeutics | SENP6, GLA, SENP1 | PDPK1 2804/4885AURKB 1906/4885AURKA 3129/4885 |
| US-20240382484-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | PDPK1, PLK3, PLK2 | PDPK1 1/4885AURKB 306/4885AURKA 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.